135 related articles for article (PubMed ID: 14510178)
41. [Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response].
Lerebours F
Pathol Biol (Paris); 2006 May; 54(4):209-14. PubMed ID: 16753495
[TBL] [Abstract][Full Text] [Related]
42. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
43. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
44. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Colomer R; Lupu R
J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
[TBL] [Abstract][Full Text] [Related]
45. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
46. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
Bult P; Tjan-Heijnen VC; van Krieken H
Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
[No Abstract] [Full Text] [Related]
47. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
Whenham N; D'Hondt V; Piccart MJ
Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058
[TBL] [Abstract][Full Text] [Related]
48. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
49. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
[TBL] [Abstract][Full Text] [Related]
50. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
51. Targeting Her-2/neu in breast cancer: as easy as this!
Azim H; Azim HA
Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
[TBL] [Abstract][Full Text] [Related]
52. Biomarkers and response to therapy in breast cancer.
Jubb AM
Clin Cancer Res; 2009 Jan; 15(1):414; author reply 414-5. PubMed ID: 19118076
[No Abstract] [Full Text] [Related]
53. New blood test can detect genes that drive cancer and help to determine best treatment.
Kmietowicz Z
BMJ; 2013 May; 346():f2825. PubMed ID: 23635918
[No Abstract] [Full Text] [Related]
54. Pharmacogenetics and breast cancer management: current status and perspectives.
Ciccolini J; Fanciullino R; Serdjebi C; Milano G
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018
[TBL] [Abstract][Full Text] [Related]
55. Cancer trials get set for biomarkers.
Bouchie A
Nat Biotechnol; 2004 Jan; 22(1):6-7. PubMed ID: 14704688
[No Abstract] [Full Text] [Related]
56. Breast cancer prognostic markers: an overview of a changing menu.
Gökmen-Polar Y; Badve S
MLO Med Lab Obs; 2015 Oct; 47(10):8, 10, 12-3; quiz 14. PubMed ID: 26591252
[No Abstract] [Full Text] [Related]
57. A menu of markers for breast cancer.
Check WA
CAP Today; 1994 Jul; 8(7):1, 20, 24-5 passim. PubMed ID: 10150193
[No Abstract] [Full Text] [Related]
58. NanoString® launches its first commercial diagnostic product.
Raison C
Expert Rev Mol Diagn; 2013 Apr; 13(3):229. PubMed ID: 23570399
[No Abstract] [Full Text] [Related]
59. Breast cancer pharmacogenomics: where we are going.
Newman WG; Flockhart D
Pharmacogenomics; 2012 Apr; 13(6):629-31. PubMed ID: 22515602
[No Abstract] [Full Text] [Related]
60. NanoString(®) launches its first commercial diagnostic product.
Raison C
Bioanalysis; 2013 May; 5(9):993. PubMed ID: 23641691
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
